SUVEN LIFE SCIENCES has announced its results for the year ended March 2022. Let us have a look at the detailed performance review of the company during FY21-22.
No. of Mths Year Ending | 12 Mar-21* | 12 Mar-22* | % Change | |
---|---|---|---|---|
Net Sales | Rs m | 135 | 118 | -12.1% |
Other income | Rs m | 78 | 53 | -31.4% |
Total Revenues | Rs m | 212 | 172 | -19.2% |
Gross profit | Rs m | -799 | -1,222 | NA |
Depreciation | Rs m | 43 | 44 | 1.1% |
Interest | Rs m | 9 | 7 | -28.8% |
Profit before tax | Rs m | -775 | -1,220 | NA |
Tax | Rs m | -53 | 0 | NA |
Profit after tax | Rs m | -722 | -1,220 | NA |
Gross profit margin | % | -593.1 | -1,032.2 | |
Effective tax rate | % | 6.9 | 0.0 | |
Net profit margin | % | -535.3 | -1,030.0 |
Read Now: We're Bullish on 2 Non-Nifty Stocks
No. of Mths Year Ending | 12 Mar-21* | 12 Mar-22* | % Change | |
---|---|---|---|---|
Networth | Rs m | 711 | 961 | 35.3 |
Current Liabilities | Rs m | 1,098 | 1,022 | -6.9 |
Long-term Debt | Rs m | 4 | 0 | -100.0 |
Total Liabilities | Rs m | 2,223 | 2,019 | -9.2 |
Current assets | Rs m | 1,966 | 1,605 | -18.4 |
Fixed Assets | Rs m | 257 | 414 | 61.0 |
Total Assets | Rs m | 2,223 | 2,019 | -9.2 |
Particulars | No. of months | 12 | 12 | % Change |
---|---|---|---|---|
Year Ending | Mar-21 | Mar-22 | ||
Cash Flow from Operating Activities | Rs m | -960 | -1,275 | - |
Cash Flow from Investing Activities | Rs m | 558 | -222 | - |
Cash Flow from Financing Activities | Rs m | 349 | 1,457 | 318.0% |
Net Cash Flow | Rs m | -53 | -41 | - |
No. of Mths Year Ending | 12 Mar-21* | 12 Mar-22* | |
---|---|---|---|
Sales per share (Unadj.) | Rs | 1.1 | 0.8 |
TTM Earnings per share | Rs | -5.7 | -8.4 |
Diluted earnings per share | Rs | -5.0 | -8.4 |
Price to Cash Flow | x | -15.1 | -12.0 |
TTM P/E ratio | x | -14.2 | -10.2 |
Price / Book Value ratio | x | 11.5 | 14.7 |
Market Cap | Rs m | 8,168 | 14,164 |
Dividends per share (Unadj.) | Rs | 0.0 | 0.0 |
Current Ratio: The company's current ratio deteriorated and stood at 1.6x during FY22, from 1.8x during FY21. The current ratio measures the company's ability to pay short-term and long-term obligations.
Interest Coverage Ratio: The company's interest coverage ratio deteriorated and stood at -181.1x during FY22, from -81.3x during FY21. The interest coverage ratio of a company states how easily a company can pay its interest expense on outstanding debt. A higher ratio is preferable.
Return on Equity (ROE): The ROE for the company declined and down at -126.9% during FY22, from -101.5% during FY22. The ROE measures the ability of a firm to generate profits from its shareholders capital in the company.
Return on Capital Employed (ROCE): The ROCE for the company declined and down at -126.2% during FY22, from -107.1% during FY21. The ROCE measures the ability of a firm to generate profits from its total capital (shareholder capital plus debt capital) employed in the company.
Return on Assets (ROA): The ROA of the company declined and down at -60.1% during FY22, from -32.0% during FY21. The ROA measures how efficiently the company uses its assets to generate earnings.
No. of Mths Year Ending | 12 Mar-21* | 12 Mar-22* | |
---|---|---|---|
Current ratio | x | 1.8 | 1.6 |
Debtors’ Days | Days | 477 | 400 |
Interest coverage | x | -81.3 | -181.1 |
Debt to equity ratio | x | 0.0 | 0.0 |
Return on assets | % | -32.0 | -60.1 |
Return on equity | % | -101.5 | -126.9 |
Return on capital employed | % | -107.1 | -126.2 |
To see how SUVEN LIFE SCIENCES has performed over the last 5 years, please visit here.
Over the last one year, SUVEN LIFE SCIENCES share price has moved down from Rs 84.2 to Rs 69.9, registering a loss of Rs 14.3 or around 17.0%.
Meanwhile, the S&P BSE HEALTHCARE Index is trading at Rs 22,981.2 (down 1.1%). Over the last one year it has moved down from 25,678.4 to 22,981.2, a loss of 2,697 points (down 10.5%).
Overall, the S&P BSE SENSEX is up 7.2% over the year.
(To know more, check out historical annual results for SUVEN LIFE SCIENCES and quarterly results for SUVEN LIFE SCIENCES)
SUVEN LIFE SCIENCES currently trades at Rs 99.7 per share. You can check out the latest share price performance of SUVEN LIFE SCIENCES here...
The revenues of SUVEN LIFE SCIENCES stood at Rs 172 m in FY22, which was down -19.2% compared to Rs 212 m reported in FY21.
SUVEN LIFE SCIENCES' revenue has fallen from Rs 6,485 m in FY18 to Rs 172 m in FY22.
Over the past 5 years, the revenue of SUVEN LIFE SCIENCES has grown at a CAGR of -59.7%.
The net loss of SUVEN LIFE SCIENCES stood at Rs -1,220 m in FY22, which was NA compared to Rs -722 m reported in FY21.
This compares to a net loss of Rs -942 m in FY20 and a net loss of Rs -239 m in FY19.
Over the past 5 years, SUVEN LIFE SCIENCES net profit has grown at a CAGR of NaN%.
The cash flow statement is the financial statement that presents the cash inflows and outflows of a company during a given period of time.
This statement is one of the most useful tools for judging a company's liquidity position. The ratios and parameters in this statement helps test a company's financial health.
The cash flow statement of SUVEN LIFE SCIENCES reveals:
Here's the cash flow statement of SUVEN LIFE SCIENCES for the past 5 years.
(Rs m) | FY18 | FY19 | FY20 | FY21 | FY22 |
---|---|---|---|---|---|
From Operations | 699 | -526 | -1,346 | -960 | -1,275 |
From Investments | -6 | 371 | 1,462 | 558 | -222 |
From Financial Activity | -521 | 45 | 28 | 349 | 1,457 |
Net Cashflow | 173 | -177 | 144 | -53 | -41 |
Be it the company's profitability, operations effectiveness or utilization of funds, ratio analysis is an important tool which helps in making investment decisions.
The ratio/financial analysis of SUVEN LIFE SCIENCES reveals:
Here's the ratio/financial analysis of SUVEN LIFE SCIENCES for the past 5 years.
FY18 | FY19 | FY20 | FY21 | FY22 | |
---|---|---|---|---|---|
Operating Profit Margin (%) | 32.3 | -3.8 | -802.8 | -593.1 | -1,032.2 |
Net Profit Margin (%) | 19.8 | -8.4 | -653.6 | -535.3 | -1,030.0 |
Debt to Equity Ratio (x) | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Read: Latest Annual Report Analysis of SUVEN LIFE SCIENCES
Equitymaster requests your view! Post a comment on "SUVEN LIFE SCIENCES 2021-22 Annual Report Analysis". Click here!
Comments are moderated by Equitymaster, in accordance with the Terms of Use, and may not appear
on this article until they have been reviewed and deemed appropriate for posting.
In the meantime, you may want to share this article with your friends!